Avenue Therapeutics, Inc. (ATXI)
OID · Healthcare · Biotechnology
$0.62
-24.76%
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
Market Cap
$2.0M
Shares Outstanding
3.3M
Exchange
OID
Currency
USD
About Avenue Therapeutics, Inc.
Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. The company product candidates include ATX-04, a small molecule therapy for the treatment of Pompe disease; and intravenous tramadol, a schedule IV opioid to treat post-operative acute pain. The company was incorporated in 2015 and is headquartered in Bay Harbor Islands, Florida.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (724K) | (955K) | (714K) | (707K) |
| Net Income | (683K) | (709K) | (695K) | (690K) |
| Diluted EPS | $-0.21 | N/A | $-0.21 | $-0.21 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 1.4M |
| Operating Income | (8.0M) | (14.5M) | (11.3M) | (3.3M) |
| Net Income | (3.6M) | (10.4M) | (11.7M) | (2.9M) |
| Diluted EPS | $-122.25 | $-73.48 | $-15.79 | $-0.93 |